Zobrazeno 1 - 5
of 5
pro vyhledávání: '"OS Pisotskaya"'
Autor:
IG Budaeva, EG Ovsyannikova, EN Goryunova, OV Kulemina, DV Zaitsev, DV Motorin, RSh Badaev, DB Zammoeva, VV Ivanov, KV Bogdanov, OS Pisotskaya, YuV Mirolyubova, TS Nikulina, YuA Alekseeva, AYu Zaritskey, LL Girshova
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 12, Iss 3, Pp 289-296 (2019)
Aim. To assess the efficacy of FLAG/FLAG-Ida regimen and to identify factors that influence remission, duration of disease-free survival (DFS) and overall survival (OS) of patients with relapsed/refractory acute myeloid leukemia (AML). Materials & Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::f7b59803d1c56f92d7d02553d8a676e5
https://doaj.org/article/5bf0b4c5df9f49f2a85bb1d94845554d
https://doaj.org/article/5bf0b4c5df9f49f2a85bb1d94845554d
Autor:
D.V. Zaitsev, YuV Mirolyubova, Konstantin Bogdanov, YuA Alekseeva, EN Goryunova, Darina Zammoeva, Larisa Girshova, EG Ovsyannikova, Irina Budaeva, AYu Zaritskey, OS Pisotskaya, TS Nikulina, Dmitry Motorin, O. Kulemina, RSh Badaev, VV Ivanov
Publikováno v:
Clinical oncohematology. 12:289-296
Aim. To assess the efficacy of FLAG/FLAG-Ida regimen and to identify factors that influence remission, duration of disease-free survival (DFS) and overall survival (OS) of patients with relapsed/refractory acute myeloid leukemia (AML). Materials & Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3eea6c0bf821bb326965581b4bf6d75e
https://doi.org/10.21320/2500-2139-2019-12-3-289-296
https://doi.org/10.21320/2500-2139-2019-12-3-289-296
Autor:
OS Pisotskaya, Darina Zammoeva, Larisa Girshova, RSh Badaev, Konstantin Bogdanov, SO Kuzin, Dmitry Motorin, VV Ivanov, Irina Budaeva, EG Ovsyannikova, YuV Mirolyubova, TS Nikulina, YuA Alekseeva, AYu Zaritskii
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 10, Iss 4, Pp 485-493 (2017)
Background. Acute myeloblastic leukemia (AML) with NPM7 mutation amounts to 30 % of all AML and is characterized by good prognosis with the exception of cases with FLT3-/TD mutation. Despite the good prognosis, the likelihood of relapses in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00ef03b2957bf164694d1c0a35f673f2
https://doi.org/10.21320/2500-2139-2017-10-4-485-493
https://doi.org/10.21320/2500-2139-2017-10-4-485-493
Autor:
YuV Mirolyubova, Dmitry Motorin, K V Bogdanov, T S Nikulina, A Y Zaritskiy, OS Pisotskaya, D V Babenetskaya, O Y Volkova
Publikováno v:
Biomeditsinskaia khimiia. 63(6)
In present research the comparative analysis of donor chimerism (DC) using different tests was performed to improve the diagnostic tool in patients with malignant hematological disorders after allo-HSCT. The RBC antigen typing, identification of ABO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95ad1e7adf676b6739aa494323c57125
https://pubmed.ncbi.nlm.nih.gov/29251621
https://pubmed.ncbi.nlm.nih.gov/29251621
Autor:
Bogdanov KV; Institute of Hematology, Federal V.A. Almazov North-West Medical Research Centre, St. Petersburg, Russia., Motorin DV; Institute of Hematology, Federal V.A. Almazov North-West Medical Research Centre, St. Petersburg, Russia., Nikulina TS; Institute of Hematology, Federal V.A. Almazov North-West Medical Research Centre, St. Petersburg, Russia., Pisotskaya OS; Institute of Hematology, Federal V.A. Almazov North-West Medical Research Centre, St. Petersburg, Russia., Babenetskaya DV; Institute of Hematology, Federal V.A. Almazov North-West Medical Research Centre, St. Petersburg, Russia., Mirolyubova YV; Institute of Hematology, Federal V.A. Almazov North-West Medical Research Centre, St. Petersburg, Russia., Volkova OY; Institute of Hematology, Federal V.A. Almazov North-West Medical Research Centre, St. Petersburg, Russia., Zaritskiy AY; Institute of Hematology, Federal V.A. Almazov North-West Medical Research Centre, St. Petersburg, Russia.
Publikováno v:
Biomeditsinskaia khimiia [Biomed Khim] 2017 Nov; Vol. 63 (6), pp. 570-581.